Progression-free survival (PFS) results

In the TARGET trial, NEXAVAR® (sorafenib)-treated patients (n=384) experienced a median PFS of 5.5 months, compared with 2.8 months for patients receiving placebo (n=385; HR=0.44; 95% CI, 0.35-0.55; P<0.000001).1

TARGET study: Median PFS1,2
Median progression-free survival data for NEXAVAR® (sorafenib)

56% reduction in risk of disease progression (PFS) with NEXAVAR vs placebo2

HR: 0.44 (95% Cl, 0.35-0.55); P<0.000001*

TARGET (Treatment Approaches in Renal Cancer Global Evaluation Trial): A randomized, double-blind, placebo-controlled, multicenter study in patients with advanced RCC who had received 1 prior systemic therapy (N=903).1,2

56%

reduction in risk of disease progression (PFS) with NEXAVAR vs placebo2

HR: 0.44 (95% Cl, 0.35-0.55); P<0.000001*

TARGET (Treatment Approaches in Renal Cancer Global Evaluation Trial): A randomized, double-blind, placebo-controlled, multicenter study in patients with advanced RCC who had received 1 prior systemic therapy (N=903).1,2

*Independently assessed data.1

  • NEXAVAR nearly doubled PFS1

  • Patients receiving NEXAVAR showed a 56% reduction in risk of progression2